Clinical Trial Update: Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lapatinib ditosylate in adults with unresectable liver and biliary tract cancers; results from the study have been posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Gallbladder Cancer
• Hepatocellular Carcinoma

Drugs mentioned

• Lapatinib Ditosylate (lapatinib ditosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-04-29